Asset Dedication LLC Has $1.42 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Asset Dedication LLC raised its position in shares of Danaher Co. (NYSE:DHR) by 2.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,099 shares of the conglomerate’s stock after purchasing an additional 122 shares during the period. Asset Dedication LLC’s holdings in Danaher were worth $1,418,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Tsfg LLC lifted its position in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the second quarter worth about $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher in the 2nd quarter valued at approximately $25,000. Redmont Wealth Advisors LLC bought a new stake in shares of Danaher during the 1st quarter valued at approximately $30,000. Finally, MFA Wealth Advisors LLC acquired a new position in Danaher during the 2nd quarter worth approximately $51,000. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DHR. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. The Goldman Sachs Group boosted their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Bank of America increased their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Stephens assumed coverage on Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective for the company. Finally, Wells Fargo & Company initiated coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price on the stock. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by company insiders.

Danaher Price Performance

Shares of DHR opened at $267.99 on Thursday. The firm has a market cap of $198.50 billion, a PE ratio of 45.42, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The business’s 50 day moving average price is $270.53 and its two-hundred day moving average price is $259.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the firm earned $2.05 earnings per share. Danaher’s revenue was down 2.9% on a year-over-year basis. On average, equities analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.